<DOC>
	<DOCNO>NCT00287430</DOCNO>
	<brief_summary>We hypothesize anabolic effect growth hormone ( GH ) improve clinical status patient CF improve lean body mass , osteopenia , muscle strength , pulmonary function , quality life . We recruit 40 malnourished CF patient 12-month study . All 40 patient treat recombinant human growth hormone ( rhGH ) . Each patient serve his/her control obtain medical record 6 month 1 year prior study enrollment complete 6 month study without GH prior treat 1 yr. GH .</brief_summary>
	<brief_title>Growth Hormone Use Adolescents Adults With Cystic Fibrosis</brief_title>
	<detailed_description>Patients treat growth hormone form Nutropin ( powder formulation reconstitute patient ) Nutropin AQ ( ready-to-use liquid ) 1 year . Both product manufacture Genentech , Inc . The start dose 0.006 mg/kg give daily subcutaneous ( SC ) injection . The GH dose titrate 1-3 month GH initiation maintain blood level IGF-1 within normal range age sex . The dose increase maximum 0.025 mg/kg daily adult patient &lt; 35 year maximum 0.0125 mg/kg daily adult patient &gt; 35 year . Pre-pubertal adolescent patient dose 0.3 mg/kg/wk 0.6 mg/kg/wk . PROCEDURES : 1 . To determine effect GH body weight lean body mass CF , weight measure baseline every three month utilize scale . LBM measure baseline every six month dual emission x-ray absorptiometry ( DEXA ) scan . 2 . To determine effect GH protein breakdown protein synthesis CF , protein turnover study perform baseline every 6 month utilize stable isotope C-leucine mass spectrophotometric analysis . Each subject undergo 30-minute measurement substrate oxidation rest energy expenditure use hood indirect calorimetry . Substrate calculation yield information glucose oxidation lipid oxidation determine use method de Weir , result correlate measurement calculate stable isotope infusion . 3 . To determine effect GH hepatic glucose production ( HGP ) follow study perform baseline every 6 month . 4 . To quantify portion hepatic glucose production ( HGP ) derive gluconeogenesis glycogenolysis post-absorptive state . We measure gluconeogenesis use stable isotope 2H2O measurement incorporation 2H 6th 2nd carbon glucose , accord method Landau 11 . 5 . To determine GH improve nutritional status CF patient follow nutritional status indicator measure 6 month interval : retinal binding protein , transferrin , thyroxine binding prealbumin , albumin , lipid profile . Additionally , caloric intake food group consumption analyze skilled dietitian 3-day food journal record every six month . 6 . To determine GH improve clinical condition CF patient , participant perform pulmonary function test , include measurement PI PE estimation respiratory muscle strength . Additionally , subject 's clinical status evaluate baseline every 3 month utilize modify NIH clinical status score system . 7 . To determine GH improve quality life CF patient , participant complete 15-minute questionnaire ass quality life . This questionnaire entitle `` The Cystic Fibrosis Questionnaire '' recently develop tested quality . It specific CF patient approve National CF Foundation . 8 . All patient random blood glucose test per CF Foundation guideline . If patient previously undiagnosed cystic fibrosis relate diabetes ( CFRD ) without fast hyperglycemia ( FH ) , he/she treat insulin minimum 3 month prior study enrollment . Patients glucose tolerance category allow participate study Also , patient previously treat insulin allow participate HgbA1C &lt; 8.5 % . If , PI adjust insulin maximize glycemic control 3 month study entry . Any patient develops CFRD without FH continue study he/she agree insulin therapy . If patient refuse insulin therapy , he/she discontinue study . Patients continue screen glucose intolerance measure random blood glucose HgbA1C . 9 . To study sustained effect GH , study subject give option continue GH additional year . The assessment perform every six month additional year . Statistics : This pilot study 40 subject . Data assess mean standard deviation . Data use compute power analysis future large study . Non-treatment data compare treatment data emphasis 12 18-month time point . Data patient develop CFRD study , , analyze separately develop CFRD .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Age 6 40 year less 100 % ideal body weight . Colonization Burkholderia cepacia pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2006</verification_date>
</DOC>